Verification evidence is still being completed.
PDF / print export
BioSpring GmbH
Frankfurt, Germany
- Verified lead
- Sylvia Wojczewski
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Co-Founder and Chief Executive Officer
- 2026 technical specialization
- Oligonucleotide CDMO, Antisense and siRNA Synthesis, mRNA and Guide RNA Manufacturing
- Review cycle
- 24 April 2026
- Full address
- Alt-Fechenheim 34, 60386 Frankfurt am Main, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- BIO Deutschland member profile confirming Sylvia Wojczewski as Co-Founder and CEO of BioSpring.
- Editorial note
- Frankfurt oligonucleotide CDMO with named co-founder CEO, cGMP since 2007, FDA-inspected commercial supply and a disclosed multi-phase Offenbach expansion creating up to 1,500 new jobs.
Oligonucleotide CDMO, Antisense and siRNA Synthesis, mRNA and Guide RNA Manufacturing
cGMP manufacturing since 2007, FDA commercial inspection, EMA and PMDA alignment
Frankfurt oligonucleotide CDMO with named co-founder CEO, cGMP since 2007, FDA-inspected commercial supply and a disclosed multi-phase Offenbach expansion creating up to 1,500 new jobs.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Frankfurt oligonucleotide CDMO with named co-founder CEO, cGMP since 2007, FDA-inspected commercial supply and a disclosed multi-phase Offenbach expansion creating up to 1,500 new jobs.
Contact & location
- Website
- biospring.net
- Company page
- Lead
- Sylvia Wojczewski (verified ↗)
- Compliance
- cGMP manufacturing since 2007 · FDA commercial inspection · EMA and PMDA alignment
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Research through multi-kilogram commercial
- Capabilities
- Antisense Oligonucleotide and siRNA Synthesis · Guide RNA and mRNA Manufacturing · Research to Commercial cGMP Scale
- Founded
- 1997
- Headcount
- 501-1000
Clinical profileSTATUS: VERIFIED APRIL 2026
Sylvia Wojczewski
Co-Founder and Chief Executive Officer
Full addressAlt-Fechenheim 34, 60386 Frankfurt am Main, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
BioSpring legal notice listing Alt-Fechenheim 34 as the Frankfurt am Main headquarters.
Open sourceResearch through multi-kilogram commercial
Frankfurt, Germany. Oligonucleotide CDMO, Antisense and siRNA Synthesis, mRNA and Guide RNA Manufacturing. Review completed on 24 Apr 2026.
BfArM, FDA, EMA, and PMDA oligonucleotide oversight
cGMP manufacturing since 2007, FDA commercial inspection, EMA and PMDA alignment
Oligonucleotide CDMO, Antisense and siRNA Synthesis, mRNA and Guide RNA Manufacturing
Frankfurt oligonucleotide CDMO with named co-founder CEO, cGMP since 2007, FDA-inspected commercial supply and a disclosed multi-phase Offenbach expansion creating up to 1,500 new jobs.
Editorial note
BioSpring is one of Europe's strongest oligonucleotide CDMO anchors, with documented cGMP operations since 2007, FDA inspections since 2016 and commercial FDA-inspected since 2020, and a public expansion into an Offenbach site with up to 1,500 new jobs announced.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Antisense Oligonucleotide and siRNA Synthesis
Guide RNA and mRNA Manufacturing
Research to Commercial cGMP Scale
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Solid-phase oligonucleotide synthesizers
Analytical and QC laboratories
Commercial-scale manufacturing suites
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is BioSpring GmbH located?
- BioSpring GmbH operates from Alt-Fechenheim 34, 60386 Frankfurt am Main, Germany, Frankfurt, Germany.
- Who runs BioSpring GmbH?
- BioSpring GmbH is led by Sylvia Wojczewski, Co-Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does BioSpring GmbH hold?
- BioSpring GmbH is documented under cGMP manufacturing since 2007, FDA commercial inspection, EMA and PMDA alignment.
- What does BioSpring GmbH do?
- Frankfurt oligonucleotide CDMO with named co-founder CEO, cGMP since 2007, FDA-inspected commercial supply and a disclosed multi-phase Offenbach expansion creating up to 1,500 new jobs. Core capabilities: Antisense Oligonucleotide and siRNA Synthesis, Guide RNA and mRNA Manufacturing, Research to Commercial cGMP Scale.
Editorial context
Related technical briefs
Briefs that name Frankfurt as a covered market or city.